Serotonin (5-HT) Receptor Modulators for Neurodegeneration

Serotonin (5-HT) Receptor Modulators for Neurodegeneration

Overview

Serotonin (5-HT) Receptor Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Serotonin (5-HT) Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">Vortioxetine</td>
<td>5-HT1A/1B/3/7 modulator</td>
</tr>
<tr>
<td class="label">Idalopirdine</td>
<td>5-HT6 antagonist</td>
</tr>
<tr>
<td class="label">Prucalopride</td>
<td>5-HT4 agonist</td>
</tr>
<tr>
<td class="label">Citalopram</td>
<td>SERT inhibitor + 5-HT effects</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">Eltoprazine</td>
<td>5-HT1B/1D agonist</td>
</tr>
<tr>
<td class="label">Buspirone</td>
<td>5-HT1A partial agonist</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>Dopamine agonist with 5-HT activity</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">5-HT2B/2C modulators</td>
<td>5-HT2B/2C</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>SERT + multiple 5-HT</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">SSRIs (sertraline)</td>
<td>SERT + multiple 5-HT</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>5-HT2A antagonist</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>SERT + multiple 5-HT</td>
</tr>
</table>

Serotonin (5-hydroxytryptamine, 5-HT) receptor modulation represents a promising therapeutic strategy across multiple neurodegenerative diseases. The serotonergic system modulates critical processes including neurogenesis, synaptic plasticity, mood, cognition, sleep, and neuroinflammation—all of which are dysregulated in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and atypical parkinsonisms like Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) [@duan2024].

The 5-HT receptor family comprises 7 families (5-HT1 to 5-HT7) with at least 14 distinct subtypes. Most are G protein-coupled receptors (GPCRs) with different signaling cascades:

• 5-HT1/5-HT5: Gi/o-coupled (inhibitory)
• 5-HT2: Gq-coupled (excitatory)
• 5-HT4/5-HT6/5-HT7: Gs-coupled (excitatory)
• 5-HT3: Ligand-gated ion channel

5-HT Receptor Families and Neurodegeneration

5-HT1 Family (Gi/o-coupled, Inhibitory)

5-HT1A Receptors

Role in Disease: 5-HT1A receptors are highly expressed in the [raphe-nuclei](/brain-regions/raphe-nuclei) (as somatodendritic autoreceptors) and in the [hippocampus](/brain-regions/hippocampus), [prefrontal-cortex](/brain-regions/prefrontal-cortex), and amygdala (as postsynaptic receptors). In AD, 5-HT1A receptor density is reduced in the temporal and frontal cortex, correlating with cognitive decline and neurofibrillary tangle burden [@lanciego2025]. In PD, 5-HT1A agonists may reduce levodopa-induced dyskinesias by modulating striatal output [@carta2017].

Therapeutic Potential:

• Buspirone: 5-HT1A partial agonist, used for anxiety in dementia patients
• Tandospirone: 5-HT1A agonist under investigation for AD behavioral symptoms
• Repinotan: 5-HT1A agonist showing neuroprotective effects in preclinical models

5-HT1B/1D Receptors

Role in Disease: Primarily presynaptic autoreceptors and heteroreceptors regulating neurotransmitter release. In PD, 5-HT1B agonists may reduce dopamine release variability and dyskinesias [@carta2017].

Therapeutic Potential:

• Eltoprazine: 5-HT1B/1D agonist in development for PD dyskinesias
• Triptans (sumatriptan, zolmitriptan) have been repurposed in preclinical models

5-HT2 Family (Gq-coupled, Excitatory)

5-HT2A Receptors

Role in Disease: Highly expressed in cortical pyramidal neurons, the 5-HT2A receptor mediates psychedelic effects and is the target of atypical antipsychotics. 5-HT2A receptor density is reduced in AD temporal and frontal cortex but may be upregulated in PD psychosis, contributing to visual hallucinations [@barnes2007].

Therapeutic Potential:

• Pimavanserin (Nuplazid): FDA-approved selective 5-HT2A inverse agonist for PD psychosis. Under investigation for AD psychosis (HARMONY trial) [@politis2015].
• Risperidone: 5-HT2A antagonist with dopamine D2 activity (used off-label for dementia agitation)
• Quetiapine: 5-HT2A antagonist with weaker D2 activity (used for PD psychosis)
• Traxopret: Novel 5-HT2A antagonist in development for AD

5-HT2C Receptors

Role in Disease: Expressed in the choroid plexus and limbic structures; regulates appetite, mood, and CSF production. Relevant to weight changes and metabolic dysfunction in neurodegenerative disease.

Therapeutic Potential:

• Lorcaserin: 5-HT2C agonist (approved for obesity, discontinued)
• Vortioxetine: 5-HT2C antagonist contributes to its procognitive effects

5-HT3 (Ligand-gated Ion Channel)

Role in Disease: The only ionotropic serotonin receptor, mediating fast excitatory neurotransmission on GABAergic interneurons and vagus nerve afferents. 5-HT3 antagonists may reduce neuroinflammation.

Therapeutic Potential:

• Ondansetron: 5-HT3 antagonist showing modest procognitive effects in preclinical AD models
• Granisetron: Under investigation for cognitive enhancement

5-HT4 (Gs-coupled, Excitatory)

Role in Disease: Expressed in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and gastrointestinal tract. 5-HT4 receptor activation promotes non-amyloidogenic [APP](/genes/app) processing and [acetylcholine](/entities/acetylcholine) release [@politis2015].

Therapeutic Potential:

• Prucalopride: 5-HT4 agonist approved for chronic constipation, showing procognitive effects in AD models
• Velusetrag: 5-HT4 agonist in clinical development for cognitive impairment
• BIMU-1: 5-HT4 agonist with anti-amyloid potential in preclinical studies

5-HT5-7 Receptors

5-HT6 Receptors

Role in Disease: Expressed exclusively in the CNS, primarily in striatum, [hippocampus](/brain-regions/hippampus), and [cortex](/brain-regions/cortex). 5-HT6 receptors modulate [acetylcholine](/entities/acetylcholine), [glutamate](/entities/glutamate), and [dopamine](/entities/dopamine) release—critical for cognition [@codony2011].

Therapeutic Potential:

• Idalopirdine (Lundbeck): 5-HT6 antagonist—failed in Phase III (LADDER trial) but pharmacological rationale remains
• Intepirdine (RxFunction): 5-HT6 antagonist—failed in Phase II/III (CONNECT trial)
• SAM-531: Next-generation 5-HT6 antagonist under development

5-HT7 Receptors

Role in Disease: Involved in circadian rhythm regulation, thermoregulation, and memory. Expressed in [hippocampus](/brain-regions/hippocampus), [thalamus](/brain-regions/thalamus), and hypothalamus. Relevant to circadian disturbances in AD and sleep disorders in PD.

Therapeutic Potential:

• AS-19: 5-HT7 agonist under investigation for circadian regulation
• SB-269970: 5-HT7 antagonist showing procognitive effects

Cross-Disease Mechanisms

Neuroprotection

5-HT receptor modulation provides neuroprotection through multiple mechanisms:

• Anti-apoptotic signaling: 5-HT1A and 5-HT2A activation triggers pro-survival pathways (PI3K/Akt, MAPK/ERK)
• Anti-inflammatory effects: 5-HT2A antagonism reduces microglial activation and cytokine release
• Anti-oxidant properties: 5-HT4 agonism enhances mitochondrial function
• BDNF upregulation: 5-HT2A and 5-HT4 signaling increases [BDNF](/proteins/bdnf) expression [@chowdhury2024]

Synaptic Plasticity

• Long-term potentiation (LTP): 5-HT4 and 5-HT6 activation enhances hippocampal LTP
• Neurogenesis: 5-HT1A and 5-HT4 agonists promote adult hippocampal neurogenesis [@lanciego2025]
• Dendritic spine formation: 5-HT2A activation stimulates spinogenesis

Neuroinflammation

Serotonergic modulation affects neuroinflammation through:

• Microglial 5-HT2B/5-HT2C receptor modulation
• T-cell 5-HT1A/5-HT7 signaling in peripheral immune-brain crosstalk
• Cytokine production modulation via 5-HT2A/5-HT7 pathways

Clinical Evidence by Disease

Alzheimer's Disease

Key findings: SSRIs reduce [amyloid-beta](/proteins/amyloid-beta) production in preclinical models [@zhang2025]. Citalopram showed modest efficacy for agitation in AD (CitAD trial) [@meltzer1998].

Parkinson's Disease

Key findings: Surviving serotonergic terminals aberrantly convert levodopa to [dopamine](/entities/dopamine), contributing to dyskinesias [@carta2017]. 5-HT2A upregulation contributes to visual hallucinations.

Amyotrophic Lateral Sclerosis (ALS)

Key findings: Reduced 5-HT levels in spinal cord of ALS patients. Serotonergic modulation affects spasticity and pseudobulbar affect.

Frontotemporal Dementia (FTD)

Key findings: Serotonergic deficits contribute to behavioral disinhibition, apathy, and compulsive behaviors in FTD.

CBS/PSP (Atypical Parkinsonism)

Key findings: Serotonergic dysfunction is prominent in PSP, contributing to depression, axial rigidity, and pseudobulbar affect.

Drug Candidates in Development

Clinical Stage

• Target: 5-HT2A inverse agonist
• Indication: PD psychosis (approved), AD psychosis, PSP
• ClinicalTrials.gov: NCT03335593 (AD psychosis), NCT02940229 (PSP)

• Target: 5-HT1A agonist, 5-HT1B partial agonist, 5-HT3 antagonist, 5-HT7 antagonist
• Indication: Depression with comorbid AD
• Status: Approved for depression, being repurposed for cognitive impairment

• Target: 5-HT4 agonist
• Indication: Cognitive impairment in AD
• Status: Phase II trials completed

• Target: 5-HT6 antagonist
• Indication: AD
• Status: Phase II completed

Preclinical Stage

Combination Strategies

Rationale for Combination Therapy

Given the complex serotonergic dysfunction in neurodegeneration, multi-target approaches may be more effective:

Examples

• Vortioxetine + Donepezil: Combined procognitive mechanisms in AD
• Pimavanserin + Levodopa: Targeted psychosis in PD without blocking dopamine
• SSRIs + 5-HT4 agonists: Enhanced neurogenesis and cognition

Biomarkers for Patient Selection

• CSF 5-HIAA: Reduced in AD and PD; indicates serotonergic denervation
• SERT PET imaging: 11C-DASB PET reveals serotonergic terminal loss
• 5-HT2A binding: Elevated in PD psychosis; predicts pimavanserin response
• Tryptophan/kynurenine ratio: Reflects immune-mediated serotonin pathway dysregulation

Challenges and Future Directions

Challenges

Future Directions

Cross-Links

• [Serotonin (5-HT) Entity Page](/entities/serotonin)
• [Serotonin Signaling in Neurodegeneration](/mechanisms/serotonin-signaling-neurodegeneration)
• [Raphe Nuclei](/brain-regions/raphe-nuclei)
• [Serotonergic Raphe Neurons](/cell-types/serotonergic-raphe-neurons)
• [5-HT1A Receptor Neurons](/cell-types/serotonin-5-ht1a-receptor-neurons)
• [5-HT2A Receptor Neurons](/cell-types/serotonin-5-ht2a-receptor-neurons)
• [5-HT4 Receptor Neurons](/cell-types/5-ht4-receptor-neurons)
• [Pimavanserin](/therapeutics/pimavanserin)
• [SSRI Antidepressants](/therapeutics/ssri-antidepressants)
• [Neurotransmitter Dysfunction in 4R Tauopathies](/mechanisms/neurotransmitter-dysfunction-4r-tauopathies)
• [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
• [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Serotonin (5-HT) Receptor Modulators for Neurodegeneration discovered through SciDEX knowledge graph analysis: